Aprepitant (APONVIE)
Substance P/Neurokinin-1 Receptor Antagonist class · 4 generic manufacturers · 10 ANDAs filed at FDA.
$12.9M in CY2024 Part D spend19K claims · 9K beneficiaries · 329 plans surveyed
Questions a plan sponsor actually asks.
What is Aprepitant used for?
Aprepitant is a Substance P/Neurokinin-1 Receptor Antagonist medication tracked in Medicare Part D.
Is there a generic for Aprepitant?
Yes. 10 ANDAs filed at FDA, 4 generic manufacturers currently shipping.
How much does my plan pay for Aprepitant?
Across 329 Part D plans, Aprepitant averages $55.86/unit (NADAC). Lowest available: $39.76/unit. Highest in distribution: $69.03/unit.
Is Aprepitant on the FDA shortage list?
No. Aprepitant is not currently on the FDA Drug Shortage Database.
6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.
Sources · every number above traces back.
Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (20 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.